Consensus Zymeworks Inc.

Stocks

ZYME

US98985Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			5-day change	1st Jan Change
28.90 ^USD	+0.17%		+2.79%	+9.76%

10-27	Zymeworks Inc. - Special Call
10-24	Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026	CI

Evolution of the Average Target: Zymeworks Inc.

Evolution of the Target Price: Zymeworks Inc.

Changes in Analyst Recommendations: Zymeworks Inc.

176c4f6799791543daf54ea228aa.O5YQpNYIjG9W_SphIczSIWfBhG09w_fbmd0ZWfs3lWk.Vv1clrtYzgoVxUhTY6eYbBKrsShVhI6v8LlpCa5k-iVJ7nnVuE_rGD-2RQ~df3a2057dd14bd059188fd837a48f9d8

Analysts' recommendations: Zymeworks Inc.

08-26	U.S. research roundup- Intuit, MongoDB, Zscaler	RE
08-10	B. Riley Adjusts Zymeworks Price Target to $44 From $40, Maintains Buy Rating	MT
12-17	Truist Initiates Zymeworks at Buy With $40 Price Target	MT
11-21	B. Riley Raises Price Target on Zymeworks to $40 From $30, Keeps Buy Rating	MT
25-10-14	HC Wainwright Upgrades Zymeworks to Buy From Neutral, Adjusts Price Target to $26 From $13	MT
25-10-13	Zymeworks Inc. to Present Clinical Data from the Phase 1 Trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor, at AACR-NCI-EORTC International Conference	CI
25-05-20	TD Cowen Initiates Coverage on Zymeworks With Buy Rating	MT
24-12-16	JPMorgan Upgrades Zymeworks to Overweight From Neutral, Adjusts Price Target to $18 From $12	MT
24-11-07	Zymeworks Shares Rise After Upgrade From Leerink Partners	MT
24-11-07	Leerink Partners Upgrades Zymeworks to Outperform, $25 Price Target	MT
24-11-01	Wells Fargo Downgrades Zymeworks to Equalweight From Overweight, PT is $12	MT
24-03-12	Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating	MT
24-03-11	H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	MT
23-05-18	Citigroup Adjusts Price Target on Zymeworks to $18 From $17, Keeps Buy Rating	MT
23-05-09	Stifel Adjusts Price Target on Zymeworks to $19 From $18, Maintains Buy Rating	MT
23-03-31	JPMorgan Raises Zymeworks' Price Target to $9 From $8, Keeps Neutral Rating	MT
23-02-13	Wells Fargo Raises Price Target for Zymeworks to $12 From $9, Maintains Overweight Rating	MT
23-01-20	SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating	MT
23-01-04	HC Wainwright Adjusts Price Target on Zymeworks to $8 From $10, Maintains Neutral Rating	MT
22-12-22	Barclays Adjusts Zymeworks Price Target to $9 From $7, Maintains Equal Weight Rating	MT
22-12-20	Jefferies Upgrades Zymeworks to Buy From Hold, Adjusts Price Target to $11 From $7.70	MT
22-11-21	HC Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	MT
22-11-01	HC Wainwright Downgrades Zymeworks to Neutral From Buy, Lowers Price Target to $8 From $40	MT
22-10-24	Stifel Adjusts Zymeworks' Price Target to $18 From $21, Reiterates Buy Rating	MT
22-10-21	SVB Securities Downgrades Zymeworks to Market Perform From Outperform, Adjusts Price Target to $8 From $19	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ZYMEWORKS INC.					+43.6%
	WUXI APPTEC CO., LTD.					+41.32%
	ARGENX SE					+28.63%
	LONZA GROUP AG					+9.56%
	IQVIA HOLDINGS INC.					+12.15%
	BEONE MEDICINES AG					+19.23%
	REVOLUTION MEDICINES, INC.					+39%
	CELLTRION, INC.					+42.31%
	GENMAB A/S					+6.5%
	WUXI BIOLOGICS (CAYMAN) INC.					+35.02%
	Average					+27.73%
	Weighted average by Cap.					+26.28%